Abstract
IA is an important cause of morbidity in cystic fibrosis lung transplant recipients (CF-LTR). Improved post-transplant care and increased use of antifungal prophylaxis after transplantation may have changed the epidemiology of IA. We assessed the epidemiology and risk factors for IA in CF-LTRs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
